Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Upcoming Clinical Trials
-
Seoul National University HospitalSamil Pharmaceutical Co., Ltd.RecruitingSarcopenia | Total Knee ArthroplastySouth Korea
-
Stanford UniversityNot yet recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative NeoplasmUnited States
-
Cheng QiRecruitingPost-hepatectomy HypoalbuminemiaChina
-
Stanford UniversityNot yet recruitingLiver FailureUnited States
-
Istanbul Aydın UniversityNot yet recruitingNeck Pain | Myofascial Pain Syndrome | Work-Related Musculoskeletal DisordersTurkey (Türkiye)
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Not yet recruitingRecurrent Endometrial Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial CancerUnited States
-
University of Colorado, DenverRecruitingAdolescent Idiopathic Scoliosis (AIS) | Neuromuscular ScoliosisUnited States
-
University of FloridaAmerican Heart AssociationRecruitingHeart Failure With Preserved Ejection Fraction (HFPEF)United States
-
UNC Lineberger Comprehensive Cancer CenterNot yet recruitingLeukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Acute Leukemia | Acute Lymphoid LeukemiaUnited States
-
Korea University Anam HospitalThe Catholic University of Korea; Keimyung University Dongsan Medical Center; Medical AI Co., LtdNot yet recruitingUrologic Cancer | Myocardial Injury After Non-cardiac Surgery | Major Adverse Cardiovascular Events (MACE)
-
Montefiore Medical CenterNot yet recruitingCesarean Scar Defect (Isthmocele)United States
-
SanofiNot yet recruiting
Clinical Research Jobs
-
Philippines - Manila
-
Taiwan - Taipei
-
United Kingdom - England - Portishead
-
United States - North Carolina - Durham
-
United StatesCanada - Québec - Quebec
-
Serbia - Belgrade
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China